摘要 |
This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity. |
主权项 |
1. A compound according to Formula (I): wherein: R1 is hydrogen, halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C3-C6)cycloalkyl, hydroxyl, (C1-C6)alkoxy, halo(C1-C6)alkoxy, (C3-C6)cycloalkoxy, amino, ((C1-C6)alkyl)amino-, or ((C1-C6)alkyl)((C1-C6)alkyl)amino-; each R2 is independently selected from the group consisting of halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C3-C6)cycloalkyl, cyano, hydroxyl, (C1-C6)alkoxy, halo(C1-C6)alkoxy, (C3-C6)cycloalkoxy, amino, ((C1-C6)alkyl)amino-, and ((C1-C6)alkyl)((C1-C6)alkyl)amino-; R3 is phenyl or 5- or 6-membered heteroaryl, each of which is optionally substituted with one to three substituents independently selected from halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C3-C6)cycloalkyl, cyano, 5- or 6-membered heteroaryl, —OR4, and —CONR5R6; wherein said (C1-C6)alkyl is optionally substituted by cyano, hydroxyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, or —NR5R6; and wherein said 5- or 6-membered heteroaryl substituent is optionally substituted by halogen, (C1-C4)alkyl, or halo(C1-C4)alkyl; R4 is hydrogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C3-C6)cycloalkyl, or 4- to 6-membered heterocycloalkyl; wherein said (C1-C6)alkyl is optionally substituted by cyano, hydroxyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, or —NR5R6; and wherein said (C3-C6)cycloalkyl is optionally substituted with one or two substituents independently selected from (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy, and halo(C1-C4)alkoxy; and wherein said 4- to 6-membered heterocycloalkyl is optionally substituted with one or two substituents independently selected from (C1-C4)alkyl and halo(C1-C4)alkyl; R5 and R6 are each independently selected from the group consisting of hydrogen, (C1-C4)alkyl, and halo(C1-C4)alkyl; or R5 and R6 taken together with the nitrogen to which they are attached represent a 5- or 6-membered saturated ring, optionally containing an additional heteroatom selected from oxygen, nitrogen, and sulfur, wherein said ring is optionally substituted by halogen, (C1-C4)alkyl, or halo(C1-C4)alkyl; and n is 0, 1, or 2; or a pharmaceutically acceptable salt thereof. |